Results 131 to 140 of about 172,168 (267)
BCR: a new target in resistance mediated by BCR/ABL-315I?
Targeting BCR/ABL with Tyrosine kinase inhibitors (TKIs) is a proven concept for the treatment of Philadelphia chromosome-positive (Ph+) leukemias but the "gatekeeper" mutation T315I confers resistance against all approved TKIs, with the only exception ...
Mian AA +5 more
core +1 more source
Supplementary Fig. S4 from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia ...
Ilene Galinsky (64265) +10 more
core +1 more source
The interaction of P160 BCR with BCR-ABL gene products unique to Philadelphia chromosome leukemias
The BCR gene is involved in the pathogenesis of Philadelphia chromosome-positive (Ph$\sp1$) leukemias. Typically, the 5$\sp\prime$ portion of BCR on chromosome 22 becomes fused to a 5$\sp\prime$ truncated ABL gene from chromosome 9 resulting in a ...
Campbell, Martin Lee
core +1 more source
BACKGROUND AND OBJECTIVE: We further characterized a novel type of chimeric BCR-ABL mRNA transcript detected in a patient with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML).
G Martinelli +9 more
doaj
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.
E. Weisberg +20 more
semanticscholar +1 more source
Supplementary Fig. S3 from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia ...
Ilene Galinsky (64265) +10 more
core +1 more source
Bcr: A conditional inhibitor of Bcr-Abl oncoprotein
Chronic myelogenous leukemia (CML) is characterized cytogenetically by the presence of the Philadelphia chromosome and clinically by the clonal expansion of the hematopoietic stem cells and the accumulation of large numbers of myeloid cells. Philadelphia
Wu, Yun
core +1 more source
Targeting HSPA8 to repress GPX4 and induce ferroptosis in BCR-ABL positive leukemia
BCR-ABL positive (BCR-ABL+) leukemia is driven by constitutive activation of tyrosine kinase activity, with tyrosine kinase inhibitors (TKIs) serving as the standard treatment. However, resistance to TKIs remains a significant clinical challenge. In this
Shuxin Zhong +12 more
doaj +1 more source
Supplementary Fig. S1 from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia ...
Ilene Galinsky (64265) +10 more
core +1 more source

